Adverse events of special interest (AEOSI) occurring in >1 subject in any treatment group in pooled phase II/III clinical trial program
| Intravenous meloxicam | ||||
| Placebo n=517 | 5–15 mg n=327 | 30 mg n=910 | 60 mg n=189 | |
| Subjects with ≥1 AEOSI, n (%) | 67 (13.0) | 41 (12.5) | 131 (14.4) | 27 (14.3) |
| Bleeding* | 11 (2.1) | 30 (9.2) | 33 (3.6) | 19 (10.1) |
| Cardiovascular | 6 (1.2) | 0 | 6 (0.7) | 2 (1.1) |
| Hepatic | 28 (5.4) | 8 (2.4) | 42 (4.6) | 5 (2.6) |
| Injection site reactions | 6 (1.2) | 0 | 12 (1.3) | 0 |
| Renal | 2 (0.4) | 0 | 8 (0.9) | 0 |
| Thrombotic | 1 (0.2) | 0 | 4 (0.4) | 0 |
| Wound healing* | 17 (3.3) | 4 (1.2) | 44 (4.8) | 3 (1.6) |
*Subjects with wound hematoma were counted once in the bleeding and once in the wound-healing categories.